Cardiorenal benefits of finerenone: protecting kidney and heart
| Autor: | José R. González-Juanatey, Jose Luis Górriz, Alberto Ortiz, Alfonso Valle, Maria Jose Soler, Lorenzo Facila |
|---|---|
| Přispěvatelé: | Institut Català de la Salut, [González-Juanatey JR] Cardiology Department, Hospital Clínico Universitario Santiago de Compostela, Centro de investigación Biomédica en Red Enfermedades Cardiovasculares (CIBERCV), Santiago de Compostela, Spain. [Górriz JL] Nephrology Department, Hospital Clínico Universitario de Valencia, Universidad de Valencia, Valencia, Spain. [Ortiz A] Nephrology Department, Fundación Jiménez Díaz, Madrid, Spain. [Valle A] Cardiology Department, Hospital La Salud, Valencia, Spain. [Soler MJ] Servei de Nefrologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Facila L] Cardiology Department, Consorcio Hospital General Universitario de Valencia, Valencia, Spain, Vall d'Hebron Barcelona Hospital Campus |
| Rok vydání: | 2023 |
| Předmět: |
enfermedades nutricionales y metabólicas::enfermedades metabólicas::trastornos del metabolismo de la glucosa::diabetes mellitus::diabetes mellitus tipo II [ENFERMEDADES]
Cardiovascular Diseases [DISEASES] Otros calificadores::/uso terapéutico [Otros calificadores] hormonas sustitutos de hormonas y antagonistas de hormonas::antagonistas de hormonas::antagonistas de receptores de mineralocorticoides [COMPUESTOS QUÍMICOS Y DROGAS] Diabetis no-insulinodependent - Complicacions enfermedades urogenitales masculinas::enfermedades urológicas::enfermedades renales::insuficiencia renal::insuficiencia renal crónica [ENFERMEDADES] Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus Type 2 [DISEASES] General Medicine Antihormones Hormones Hormone Substitutes and Hormone Antagonists::Hormone Antagonists::Mineralocorticoid Receptor Antagonists [CHEMICALS AND DRUGS] Insuficiència renal crònica - Complicacions Sistema cardiovascular - Malalties - Diagnòstic Male Urogenital Diseases::Urologic Diseases::Kidney Diseases::Renal Insufficiency::Renal Insufficiency Chronic [DISEASES] Other subheadings::/therapeutic use [Other subheadings] enfermedades cardiovasculares [ENFERMEDADES] |
| Zdroj: | Scientia |
| ISSN: | 1365-2060 0785-3890 |
| DOI: | 10.1080/07853890.2023.2171110 |
| Popis: | Albuminuria; Enfermedad renal crónica; Finerenona Albuminúria; Malaltia renal crònica; Finerenona Albuminuria; Chronic kidney disease; Finerenone Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of developing cardiovascular (CV) complications despite treatment with renin-angiotensin system blockers and sodium-glucose cotransporter type 2 inhibitors. Overactivation of mineralocorticoid receptors plays a key role in the progression of renal and CV disease, mainly by promoting inflammation and fibrosis. Finerenone is a nonsteroidal selective mineralocorticoid antagonist. Recent clinical trials, such as FIDELIO-DKD and FIGARO-DKD and the combined analysis FIDELITY have demonstrated that finerenone decreases albuminuria, risk of CKD progression, and CV risk in subjects with type 2 diabetes (T2D) and CKD. As a result, finerenone should thus be considered as part of a holistic approach to kidney and CV risk in persons with T2D and CKD. In this narrative review, the impact of finerenone treatment on the CV system in persons with type 2 diabetes and CKD is analyzed from a practical point of view. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|